High Levels of Perimenopause-Related Symptoms Seen in Younger Women
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
TUESDAY, March 4, 2025 -- A significant number of individuals aged 30 to 45 years experience perimenopause-related symptoms, according to a study published online Feb. 25 in npj Women's Health.
Adam C. Cunningham, from Flo Health, Inc., in London, and colleagues surveyed 4,432 U.S. women (aged 30 years and older) about clinical help-seeking and the presence and severity of perimenopause symptoms using the Flo app.
The researchers found that 20.7 percent of respondents had consulted a medical professional about perimenopause or menopause, including 30.3 percent who were younger than 46 years. Among those seeking consultation, more than a quarter of 30- to 35-year-olds and 40 percent of 36- to 40-year-olds had been told they were perimenopausal. Urogenital symptoms, psychological symptoms, and somato-vegetative symptoms significantly differed by age group, with Menopause Rating Scale total score and the somato-vegetative domain score highest in those aged 51 to 55 years, while the psychological domain score was highest in the 41- to 45-year-old age group.
"This study is important because it plots a trajectory of perimenopausal symptoms that tells us what symptoms we can expect when and alerts us to the fact that women are experiencing perimenopausal symptoms earlier than we expected," coauthor Jennifer Payne, M.D., from the University of Virginia in Charlottesville, said in a statement.
Several authors disclosed ties to Flo Health.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-03-05 12:00
Read more

- Newborns With Seizures At Greater Risk of Epilepsy
- A Suicide Death Occurs Every 43 Seconds Worldwide
- Boston Surgeons Successfully Transplant Pig Kidney in Fourth Patient
- EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of Duravyu for Diabetic Macular Edema Meeting Primary and Secondary Endpoints
- Behavioral, Developmental Disorders in Children More Common in Recent Years
- Exercises for a Healthy Heart
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions